Skip to content


Integrilin (eptifibatide) is a protein pharmaceutical. Eptifibatide was first approved as Integrilin on 1998-05-18. It is used to treat coronary disease, myocardial infarction, and unstable angina in the USA. It has been approved in Europe to treat myocardial infarction and unstable angina.
Trade Name Integrilin
Common Name Eptifibatide
Indication coronary disease, myocardial infarction, unstable angina
Drug Class Peptides: platelet aggregation inhibitors (glycoprotein IIb/IIIa receptor antagonists)
Get full access now